Pfizer to launch Phase 2/3 study of COVID antiviral in pediatric patients

Pfizer Inc. said Wednesday it is starting a Phase 2/3 trial of its COVID-19 antiviral in children below the age of 18 who are at high risk of developing severe illness. The aim of the study is to treat children outside of a hospital setting with the five-day treatment Paxlovid, which has been granted an emergency use authorization by the U.S. Food and Drug Administration for high-risk adults and high-risk pediatric patients aged 12 years and older that weigh at least 40 kg. "Since the...